Mirae Asset Global ETFs Holdings’s ImmunityBio IBRX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.91M	Buy	218,256 +41,327	+23%	+$313K	﹤0.01%	1275
2026 Q1	$1.32M	Buy	176,929 +4,438	+3%	+$30.4K	﹤0.01%	1384
2025 Q4	$342K	Buy	172,491 +41,320	+32%	+$93.6K	﹤0.01%	2087
2025 Q3	$325K	Sell	131,171 -7,179	-5%	-$18.5K	﹤0.01%	2070
2025 Q2	$366K	Buy	138,350 +32,726	+31%	+$88K	﹤0.01%	1967
2025 Q1	$320K	Buy	105,624 +750	+0.7%	+$2.27K	﹤0.01%	2084
2024 Q4	$271K	Buy	104,874 +9,305	+10%	+$38.8K	﹤0.01%	2235
2024 Q3	$359K	Buy	95,569 +12,460	+15%	+$57.7K	﹤0.01%	2082
2024 Q2	$529K	Buy	+83,109	New	+$548K	﹤0.01%	1799

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's IBRX Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its ImmunityBio (IBRX) stake by 23% in Q2 2026, buying an estimated $313K and bringing the position to 218,256 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #1275.

Mirae Asset Global ETFs Holdings first reported a position in IBRX in Q2 2024 and has held it in 9 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Mirae Asset Global ETFs Holdings held 218,256 shares of ImmunityBio worth $1.91M as of Q2 2026.
Mirae Asset Global ETFs Holdings bought 41,327 ImmunityBio shares in Q2 2026, an estimated $313K.
ImmunityBio made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1275 holding.
Mirae Asset Global ETFs Holdings first reported a position in ImmunityBio in Q2 2024 and has held it in 9 quarters since.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.